FDA Drugs (New Approvals & NDA)Original article
Determining Whether to Submit an ANDA or a 505(b)(2) Application
RegulatoryNeutral
AI Analysis
Summary
FDA guidance article on determining whether to submit an Abbreviated New Drug Application (ANDA) or a 505(b)(2) application. This is educational regulatory content with no specific company, drug, or catalyst information.
Importance:2/10
Sentiment:
0.00
ANDA505(b)(2)FDAregulatory guidancegeneric drugs
Read the original article
Published by FDA Drugs (New Approvals & NDA) on August 17, 2026 2:29 PM